A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Abstract

Abstract Introduction Panobinostat is a pan-deacetylase inhibitor with activity against all class I, II, and IV histone deacetylase enzymes, including those implicated as potential targets in MM. Panobinostat increases acetylation of histones 2, 3 and 4 (H2, H3 and H4) and proteins involved in multiple oncogenic pathways, including the aggresome protein degradation pathway. Panobinostat has not been systematically evaluated as a single agent in patients with MM, however activity was demonstrated in patients with advanced MM in phase I and II trials. This, coupled with preclinical data, favorable toxicity profile and oral formulation strongly suppo..